AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive Officer effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer effective July 18, 2025, in order to pursue another opportunity. Additionally, Kyle Kline, Senior Vice President of Fi ...

Company Developments - Globus Medical, Inc. (GMED) has launched DuraPro, a next-generation oscillating system with Excelsius navigation capabilities, aimed at enhancing procedural workflows through improved safety and efficiency [1][8] - The company has introduced 18 new products in 2024, including the ExcelsiusHub and ExcelsiusFlex surgical navigation systems, and expanded its Advanced Materials Science implant portfolio with the COHERE ALIF Spacer in Q1 2025 [3] - The DuraPro system features advanced oscillating technology that prevents soft tissue wrapping and allows for accurate bone removal while protecting delicate tissue [5][8] - GMED has also launched Verzera, a navigated high-speed drill system that integrates with ExcelsiusGPS and ExcelsiusHub, enhancing surgical workflows [6] Financial Performance and Market Outlook - GMED has a market capitalization of $7.56 billion, with 2025 revenue expected to rise by 12.8% year over year according to the Zacks Consensus Estimate [4] - The company has delivered an average earnings surprise of 10.1% over the trailing four quarters [4] - Despite recent product launches, GMED shares have declined by 23.2% over the past year, compared to a 13.7% decline in the industry [11] Industry Trends - The global high-speed surgical drill market is projected to grow from $2.44 billion in 2025 at a compound annual growth rate of 7.8% from 2025 to 2033, driven by the rise in minimally invasive surgical procedures and technological advancements [9]

Core Viewpoint - Globus Medical, Inc. has expanded its Excelsius™ navigation capabilities with the introduction of the DuraPro™ oscillating system, aimed at enhancing procedural workflows through improved safety and efficiency [1][5]. Group 1: Product Innovation - The DuraPro™ system is designed to revolutionize the $550 million high-speed drill market with next-generation oscillation technology [2]. - DuraPro™ helps prevent soft tissue wrapping while providing a natural sensation similar to conventional spinning drills, allowing for efficient and accurate bone removal [3]. - The system features anti-skiving pilot hole drilling, maintaining drill tip trajectories and facilitating thorough discectomies [3]. Group 2: Integration and Workflow Enhancement - DuraPro™ integrates seamlessly with ExcelsiusGPS™ and ExcelsiusHub™, supporting accuracy and efficiency in both navigated and non-navigated workflows [3]. - The newly launched Verzera™ system, also integrated with ExcelsiusGPS and ExcelsiusHub, enhances existing workflows for surgeons by allowing navigation during bone removal procedures [4]. Group 3: Commitment to Clinical Needs - The expanded Power Portfolio reflects Globus Medical's commitment to addressing unmet clinical needs and providing surgeons with enhanced confidence through integrated technology [5].

Core Insights - Shares of Globus Medical (NYSE: GMED) have experienced a significant decline this year following a weak performance in the first quarter [1] - The decline was somewhat anticipated, as caution was advised in February after the company's announcement [1] Company Performance - The first quarter performance of Globus Medical was described as soft, contributing to the stock's downturn [1] - The company is under scrutiny for its financial results and market position following the disappointing earnings report [1] Investment Opportunities - The investing group "Value In Corporate Events" focuses on identifying actionable investment opportunities related to major corporate events such as earnings reports, M&A, and IPOs [1] - The group aims to provide coverage of 10 major events monthly to find the best investment opportunities [1]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Globus Medical reported financial results for Q1 2025, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06, and revenue of $598.12 million, which was $27.78 million below expectations and represented a 1.4% year-over-year decline [3] - Following the disappointing financial results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3] Financial Performance - Non-GAAP earnings per share for Q1 2025 were reported at $0.68, missing estimates by $0.06 [3] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and showing a 1.4% decline compared to the previous year [3] - The decline in performance was attributed to softer deal closures, supply chain disruptions, and timing issues with international distributor orders [3] Stock Market Reaction - The stock price of Globus Medical experienced a significant drop of $16.64 per share, equating to a 22.96% decrease [3] - The closing price after the drop was $55.82 per share on May 9, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, which was $0.06 below consensus estimates [3]. - The company's revenue for Q1 2025 was $598.12 million, missing consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders, as stated by the President and CEO of Globus [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [3] - The company reported revenue of $598.12 million, which was $27.78 million below consensus estimates and represented a 1.4% year-over-year decline [3] - Following the financial results announcement, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [3] Company Challenges - The decline in financial performance was attributed to softer Enabling Technology deal closures, temporary integration-related supply chain disruptions, and the timing of international distributor orders [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, which was $0.06 below consensus estimates [3]. - The company's revenue for Q1 2025 was $598.12 million, missing consensus estimates by $27.78 million and reflecting a 1.4% decline year-over-year [3]. - Following the announcement of these results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to softer deal closures in Enabling Technology, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported Q1 2025 financial results, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [2] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [2] - The decline in performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [2] Market Reaction - Following the financial results announcement, Globus's stock price dropped by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. following disappointing financial results for Q1 2025, which led to a significant drop in the company's stock price [1][3]. Financial Performance - Globus Medical reported non-GAAP earnings per share of $0.68 for Q1 2025, missing consensus estimates by $0.06 [3]. - The company's revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price decreased by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to several factors, including softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].